Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40493744.
- Also identified by DOI 10.1093/cid/ciaf302.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.
Medical subject headings
- COVID-19
- T-Lymphocytes
- Immunocompromised Host